Live Markets
Tuesday, July 28, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

RxSight, Inc. (RXST)

NGM · Medical Devices

$6.05+0.41 (+7.27%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$250.4M
P/E (TTM)
EPS
$-1.21
Div Yield
52W Range
$4.48–$13.22
Beta
1.15

Company overview

Next earnings: 2026-08-05(8d)

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Peers in Medical Devices

All in industry →

Recent press releases

RxSight, Inc. has not issued a press release in this window.

SEC filings

All filings →

RxSight, Inc. has not filed an SEC document in this window.

RxSight, Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
2,000,060 sh● NEW
19,307 sh-98.1%
1,230,853 sh+692.6%
913,090 sh● NEW
2,157,264 sh+23.0%
1,975,000 sh+21.5%
531,730 sh+609.7%
2,229,539 sh+3.8%

People at RxSight, Inc.

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
$27.2M
NI -$8.2M
06/25
$27.0M
NI -$11.8M
09/25
$30.3M
NI -$9.8M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.24
Prior: $-0.29
Revenue sparkline